I-\textit{kappa}-kinase-2 (IKK-2) inhibition potentiates vincristine cytotoxicity in non-Hodgkin’s lymphoma

Ayad Al-Katib\textsuperscript{1*}, Alan A Arnold\textsuperscript{2†}, Amro Aboukameel\textsuperscript{1}, Angela Sosin\textsuperscript{1}, Peter Smith\textsuperscript{3}, Anwar N Mohamed\textsuperscript{4}, Frances W Beck\textsuperscript{5}, Ramzi M Mohammad\textsuperscript{6}

Abstract

\textbf{Background:} IKK-2 is an important regulator of the nuclear factor-\textit{kappa}B (NF-\textit{kappa}B) which has been implicated in survival, proliferation and apoptosis resistance of lymphoma cells. In this study, we investigated whether inhibition of IKK-2 impacts cell growth or cytotoxicity of selected conventional chemotherapeutic agents in non-Hodgkin’s lymphoma.

Two established model systems were used; Follicular (WSU-FSCCL) and Diffuse Large Cell (WSU-DLCL2) Lymphoma, both of which constitutively express p-NF-\textit{kappa}B. A novel, selective small molecule inhibitor of IKK-2, ML120B (N-[6-chloro-7-methoxy-9H-b-carbolin-8-yl]-2-methylnicotinamide) was used to perturb NF-\textit{kappa}B in lymphoma cells. The growth inhibitory effect of ML120B (M) alone and in combination with cyclophosphamide monohydrate (C), doxorubicin (H) or vincristine (V) was evaluated \textit{in vitro} using short-term culture assay. We also determined efficacy of the combination \textit{in vivo} using the SCID mouse xenografts.

\textbf{Results:} ML120B down-regulated p-NF-\textit{kappa}B protein expression in a concentration dependent manner, caused growth inhibition, increased G0/G1 cells, but did not induce apoptosis. There was no significant enhancement of cell kill in the M/C or M/H combination. However, there was strong synergy in the M/V combination where the vincristine concentration can be lowered by a hundred fold in the combination for comparable G2/M arrest and apoptosis. ML120B prevented vincristine-induced nuclear translocation of p65 subunit of NF-\textit{kappa}B. \textit{In vivo}, ML120B was effective by itself and enhanced CHOP anti-tumor activity significantly (P = 0.001) in the WSU-DLCL2-SCID model but did not prevent CNS lymphoma in the WSU-FSCCL-SCID model.

\textbf{Conclusions:} For the first time, this study demonstrates that perturbation of IKK-2 by ML120B leads to synergistic enhancement of vincristine cytotoxicity in lymphoma. These results suggest that disruption of the NF-\textit{kappa}B pathway is a useful adjunct to cytotoxic chemotherapy in lymphoma.

Background

NHL is the fifth most common type of cancer in the US representing 4.5% of cancer cases. Since the early 1970’s the incidence of NHL has doubled [1]. It is a group of heterogeneous diseases resulting from malignant transformation of lymphocytes. Eighty-five percent of NHLs are B-cells that can be broadly classified as aggressive (50%) and indolent (40%). Diffuse Large B-cell NHL (DLBCL) is the most common subtype (30%) of all lymphomas and is the prototype of aggressive but curable NHL. Follicular lymphoma (FL) is the second most common subtype, representing 22% and is the most common indolent NHL [2,3].

To date, there is no consensus concerning the best treatment algorithm, but combination chemotherapy has been the mainstay for treatment of NHL. Incorporation of the anti-CD20 monoclonal antibody, Rituximab, has led to improvements in overall survival [4,5]. More than half of patients with DLBCL can be cured with combination of Rituximab (R) and cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP). Incorporating...
Rituximab into conventional chemotherapy for follicular lymphoma has lead to higher response rates and longer durations of remission compared with chemotherapy alone [6]. The success of Rituximab suggests that additional targeted therapeutics might improve the efficacy of cytotoxic regimens.

Constitutively active NF-κB in lymphoma is known to induce resistance to intrinsic and extrinsic apoptosis pathways [7]. NF-κB is a transcription factor comprised of homo- and heterodimers, p50/p105 (NF-κB1), p52/p100 (NF-κB2), c-Rel, RelB, and p65 (RelA) [8]. Inhibitors of kappa B (IκBα, IκBβ) and IκBε) contain ankyrin-like repeats that mediate sequestration of NF-κB in the cytosol [9]. The interaction between IκBα and NF-κB is regulated by IκB kinase (IKK-1 and IKK-2). Phosphorylation of IκBα leads to its degradation and release of NF-κB. NF-κB is then able to translocate to the nucleus where it controls a number of molecules involved in vital cellular functions, such as proliferation, apoptosis, and resistance to chemotherapy [10-16].

Clinically, aberrant NF-κB activation has been linked to poor outcome in lymphomas [17,18]. Therefore, these and other studies prompted us to investigate potential therapeutic effects of inhibiting components of the NF-κB activation pathway in our lymphoma models.

Small molecule inhibitors (SMI) are used to selectively target molecules involved in survival pathways. ML120B (N-[6-chloro-7-methoxy-9H-β-carbolin-8-yl]-2-methylnicotinamide) is a potent and selective inhibitor of IKK-2, acting through blockade of the ATP-binding site in the kinase. ML120B has been shown to inhibit tumor necrosis factor-α (TNF-α)-induced nuclear translocation of p65 subunit of NF-κB and block TNF-α-stimulated cytokine production in human fibroblast-like synovial cell cultures isolated from patients with rheumatoid arthritis [19]. ML120B inhibits both baseline and TNF-α-induced NF-κB activation in multiple myeloma cells. It was also shown to inhibit the growth of multiple myeloma cells in vitro and in vivo SCID mouse models [20].

In this report, we show that ML120B inhibits the phosphorylation of IκBα, hinders the growth of lymphoma cell lines in a concentration- and time-dependent manner and reduces progression out of G0/G1 phase of the cell cycle. More importantly, ML120B has a synergistic interaction with vincristine, a common cytotoxic agent used in the treatment of hematological malignancies. Our studies suggest that IKK-2 inhibition has a therapeutic role in lymphoma when used alone or in combination with cytotoxic agents.

**Results**

**Inhibition of IKK-2 Leads to Growth Inhibition of Lymphoma Cell Lines**

In order to determine whether perturbation of the NF-κB activation pathway might play a survival role in our lymphoma models, we seeded lymphoma cells in cluster plates and treated the cells with ML120B at 0 to 80 μM. ML120B inhibited the growth of our cells in a concentration- and time-dependent manner. After 48 hours of incubation, the IC_{50} values were 18.8 and 23.2 μM for WSU-FSCCL and WSU-DLCL₂ cells, respectively (Figure 1A). Accumulation of cells in sub G0/G1 fraction was not seen, indicating absence of apoptosis (data not shown). Instead, there was a concentration-dependent increase in cells arrested at G0/G1 and a reciprocal decrease of cells in S-phase (Figure 1B). ML120B (40 μM) induced a statistically significant increase of cells in G0/G1: 14% and 31% in WSU-FSCCL and WSU-DLCL₂ (P = 0.02 and 0.01), respectively.

The WSU-FSCCL and WSU-DLCL₂ cells exhibit constitutive NF-κB activation as shown by the baseline expression of the phosphorylated form of IκBα (p-IκBα). ML120B inhibited phosphorylated IκBα in a concentration-dependent manner within one hour incubation with these cells. At 20 μM, ML120B inhibited p-IκBα by 100% in WSU-FSCCL and 40% in WSU-DLCL₂ compared to control (Figure 1C).

**IKK-2 Inhibition in Combination with Conventional Chemotherapeutic Agents**

Since CHOP is currently the standard regimen for lymphoma therapy, we chose to investigate the effects of IKK-2 inhibition in combination with the cytotoxic components of CHOP in WSU-FSCCL, i.e. cyclophosphamide monohydrate (C), doxorubicin (H), and vincristine (V). The drug concentrations used were adopted from experiments in the WSU-DLCL₂ cells as previously determined in our lab [21]. When used together, the IC_{50} for WSU-DLCL₂ were as follows: C = 5.84 pM; H = 1.5 pM; and V = 260 pM. However, when these drugs used individually against WSU-FSCCL in this study, we obtained less than 50% growth inhibitions at 48 hours: C = 38% (i.e. IC_{40}); H = 24% (i.e. IC_{25}); and V = 39% (i.e. IC_{40}). WSU-FSCCL cells were pre-incubated with ML120B for 1 hour at IC_{50} (18.8 μM) prior to addition of cytotoxic agents. The M/C combination did not induce growth inhibition greater than the individual agents alone (Figure 2A & Table insert D). Similar results were obtained with M/H combination (Figure 2B & Table insert D). However, the M/V combination induced significant growth inhibition greater than either agent alone (Figure 2C & Table insert D). To determine if this interaction is synergistic, WSU-FSCCL cells were
incubated with both agents at varying concentrations and the fractional effect of both agents alone and in combination was calculated (Figure 2F). The M/V combination at 20 μM: 260 pM yielded a CI value of 0.225 which correlates with "strong synergism". Increasing concentration of the agents yielded "very strong synergism". Notably, M/V combination at lower concentration (10/130) also yielded "synergism" (Table insert E in Figure 2).

**ML120B: Vincristine Combination Induces G2/M Cell Cycle Arrest and Apoptosis**

When used alone against the WSU-FSCCL cells, vincristine at 520 pM induced G2/M arrest at 24 hours which was released at subsequent time points (Figure 3A). Vincristine at its IC₄₀ (260 pM) did not induce significant G2/M arrest compared to control. Higher concentrations of vincristine (50 nM to 0.2 μM) were previously shown to induce G2/M arrest in cancer cells [22,23]. Vincristine, at a concentration of 50 nM in our WSU-FSCCL cells induced a sustained G2/M arrest over the 72 hour incubation period (Figure 3A). In the combination studies, the general effects on cell cycle were similar but the magnitude was different depending on the concentration of the 2 compounds. The most dramatic effect was seen with the higher concentrations (M 40 μM: V 520 pM) which showed a significant increase in G2/M at 24 hrs at the expense of S and G0/G1 (Figure 3A). With further incubation (48 and 72 hrs), there was relative increase in G0/G1 suggesting that cells arrested in G2/M at 24 hrs underwent apoptosis. In support of this interpretation is the increase of cells in sub-G0
shown in Figure 3C. The combination of 40:520 M(μM): V(pM) induced a G2/M arrest at 24 hours that was not statistically different from the 50 nM vincristine. The combination of the two agents had a statistically significant concentration- and time-dependent increase in apoptotic sub G0/G1 fraction of cells. The increase in the apoptotic fraction induced by the combination was higher compared to that found in both the control and 50 nM vincristine at 24 hours (Figure 3C). At 48 hours, the M/V combination at 40 μM: 520 pM induced comparable apoptosis to the higher concentration of single agent vincristine (50 nM). However, at 72 hours, the high concentration of vincristine alone was more effective. Of special interest is our observation that neither ML120B nor vincristine alone (at concentrations up to 40 μM and 520 pM, respectively) induced sub G0/G1 accumulation (Figure 3D). Therefore, our data suggest that the M/V combination induces an initial G2/M arrest at 24 hours, followed by apoptosis at 48 and 72 hours, leaving a fraction of unaffected cells arrested in G0/G1. We used TUNEL assay to confirm that apoptosis occurred mostly in G2/M. Figure 4A shows the increasing FITC positive population in treated cells compared with control (horizontal axis). Total FITC positive cells also increased with increasing time of incubation and concentration of M:V. For example, the total number of FITC positive cells in the highest concentration of M:V combination (bottom line, panel B, Figure 4) increased from 12.75% at 24 h to 43.46% at 48 h and to 51.33% at 72 h. Moreover, there was progressive shift-to-the-right of FITC positive cell population with increasing incubation indicating increasing intensity of DNA breaks (apoptosis). Most of the FITC positive cells were in G2/M phase followed by sub G0/G1 (which indicates late apoptosis). Some apoptosis did occur from G0/G1 at 72 h. Induction of apoptosis was
Figure 3 ML120B:vincristine combination induces cell cycle arrest and apoptosis. Flow cytometric analysis of cell cycle was done following PI staining of WSU-FSCCL cells. A. WSU-FSCCL cells were exposed to vincristine (V) for the indicated times and concentrations. B. WSU-FSCCL cells were pretreated with ML120B (M) for 60 minutes followed by vincristine (V) at the indicated concentrations and times. C. Apoptotic cells (Sub G0) analyzed by PI staining using flow cytometry in WSU-FSCCL for combinational treatments, Mean and standard error of mean (SEM). D. Apoptotic cells analyzed as in (C) in WSU-FSCCL cells treated with single agents.
also confirmed independently using 7-amino-actinomycin D (7-AAD) staining as shown in Figure 5.

Mechanism of Interaction Between IKK-2 Inhibition and Vincristine
To define some of the molecular mechanisms by which ML120B synergizes with vincristine in WSU-FSCCL cells, we first evaluated selected markers of apoptosis. There was only minimal activation of apoptosis executioner (caspase-3) by each agent alone (Figure 6). However, the ML120B: vincristine combination induced caspase-3 cleavage. The combination also significantly induced PARP cleavage. Both agents, individually and in combination, enhanced the expression of cleaved caspase 8. These findings support the flow cytometry data presented in Figures 3, 4, 5 showing that ML120B: vincristine combination induces significant apoptosis whereas neither agent alone has significant effect at the concentrations used in this study. These data also support the synergistic growth inhibitory effect shown in Figure 2. To explain such synergy, we evaluated the effects of different treatments on p65 in WSU-FSCCL cells by western blots and immunofluorescence. As shown in Figure 6, exposure of cells to ML120B led to retention of p65 in the cytosol and reduction in nuclear p65. This finding is consistent with published data [19] and with our finding that ML120B inhibits the phosphorylation, and subsequent degradation, of IκBα (Figure 1). Vincristine, on the other hand, decreased the cytosolic p65 expression indicating p65 translocation to the nucleus and activation of NF-κB pathway. This finding is consistent with published data demonstrating that vincristine and other microtubule inhibitors activate NF-κB [24]. In the combination treatment where cells are
exposed to ML120B for one hour prior to vincristine, p65 was sequestered in the cytosol comparable to levels of ML120B-alone treated cells. These findings were confirmed by immunofluorescence studies (Figure 7) and led us to hypothesize that ML120B synergizes with vincristine by preventing vincristine-induced activation of NF-κB pathway. As a transcription factor, NF-κB controls many molecules that are associated with resistance to programmed cell [3,17,18].

Antitumor Activity of ML120B in Lymphoma-bearing SCID Mice

Finally, we determined the efficacy of ML120B in our lymphoma-bearing xenograft SCID mouse models. ML120B did not prevent WSU-FSCCL from infiltrating into the CNS in this systemic model (data not shown). It was not possible, therefore to determine its systemic efficacy since the usual cause of animal death is CNS lymphoma [25]. Conversely, ML120B delayed the growth of WSU-DLCL2 SC tumors. In Figure 8A, single day doses did not induce significant tumor growth delay. However, a 28-day course showed significant delay in tumor growth compared to single day doses (P = 0.03) and to control (P = 0.04). To determine whether our in vitro combination findings correlated in vivo, we compared ML120B with CHOP at its MTD. Figure 8B, shows that CHOP and ML120B significantly reduced tumor load when given alone compared to control (P = 0.003 and 0.006, respectively). ML120B: CHOP combination significantly delayed tumor growth compared to control (P = 0.003), CHOP alone (P = 0.003), and ML120B alone (0.001). This data indicate that IKK-2 inhibition potentiates conventional cytotoxic chemotherapy effect in vivo.
In this study we show that inhibition of IKK-2 by a small molecule inhibitor, ML120B, enhances the cytotoxic effect of the microtubule inhibitor, vincristine in lymphoma cells. IKK-2 inhibition leads to sequestration of p65 in the cytosol and prevention of vincristine-induced nuclear translocation. It was previously shown that NF-κB activation is involved in vincristine resistance [26]. This is believed to be due, at least in part, to the positive effect of NF-κB on cell cycle progression [27].

There are multiple approaches to target IKK-2/NF-κB pathway. Several specific IKK-2 inhibitors are under development (reviewed by Karin et. al [28]). These inhibitors have a wide range of IC50 in relationship to inhibiting IKK-2. For example, the IC50 of SPC-839, PS-1145, and BMS-345541 are 62 nM, 0.15 μM, and 0.3 μM, respectively. ML120B inhibits IKK-2 at an IC50 of 62 nM. ML120B, in the nM range is highly specific to IKK-2, but is capable of inhibiting IKKe and other enzymes at an IC50 greater that 100 μM [29]. Other novel SMIs, such as GS143 suppress IκBα ubiquitination, but not IκBα phosphorylation.

Thus, inhibition of NF-κB activation is as complex as the activation pathway itself with multiple sites as targets for inhibition [30].

The present study makes several key observations regarding IKK-2 as a potential therapeutic target in lymphoma. First, we demonstrated that inhibition of IKK-2 by ML120B can cause growth inhibition in a concentration- and time-dependent manner. The cause of the growth inhibition was due to the increase of cells in G0/G1 phase of the cell cycle. Our results suggest that ML120B alone acts by blocking cell growth and not via apoptosis. Second, we demonstrated that ML120B can inhibit constitutive activation of NF-κB in indolent and aggressive lymphoma cell lines in a concentration dependent manner similar to what was observed in myeloma cells [20]. These observations suggest a broad application of IKK-2 inhibition in lymphoid tumors.

Interestingly, our data shows that IKK-2 inhibition synergizes the cytotoxic effects of microtubule inhibitor, vincristine. This synergy was found at 1/100 the dose of vincristine alone required to induce comparable G2/M arrest and apoptosis (520 pM in combination with ML120B (40 μM) vs 50 nM when used alone, Figure 3A-C). Furthermore, our results suggest that the ML120B: vincristine combination induces cell cycle arrest followed by apoptosis out of G2/M. Vincristine is a microtubule depolymerizing agent. It was shown that depolymerization of microtubules activates NF-kB and induces NF-kB-dependent gene expression [31]. Our data indicate that prevention of vincristine-induced nuclear translocation of p65 and activation of NF-κB is a major mechanism of synergy between IKK-2 inhibition and vincristine. This synergy is selective since we did not observe similar interaction between IKK-2 inhibition and cyclophosphamide or doxorubicin. Cell death induced by the ML120B: vincristine combination is through the apoptosis pathway since there was evidence for caspase 3 and PARP cleavage (Figure 6). Constitutive activation of NF-κB in lymphoma and consequent activation of downstream molecules like cIAP2 [32], p21 [33], and Bcl-2 [12] increases the threshold for apoptosis. This cell survival mechanism is accentuated by exposure of cells to vincristine [24,33]. IKK-2 inhibition, by sequestering NF-κB in the cytosol and consequent down regulation of pro-survival molecules, lowers the threshold of apoptosis in response to cytotoxic agents like vincristine (Figures 3, 4, 5).

In vivo, we showed that ML120B: CHOP combination was well tolerated by the animals and induced higher anti-tumor efficacy compared with each agent alone in our WSU-DLCL2-SCID model (Figure 8). We have previously shown that genistein (30 μM) sensitizes DLCL2 cells to CHOP [24]. Bharti et al., have shown that curcumin, a natural inhibitor of NF-κB, may sensitize the
cytotoxic effects of vincristine (50 μM) [34]. Sanda et al., showed that IKK inhibition by ACHP (10 μM) led to growth inhibition of MM cells and potentiation of vincristine cytotoxicity [35].

Conclusion
In summary, our study shows the feasibility of inhibiting a constitutively active NF-κB pathway in lymphoma cells. Such inhibition is associated with therapeutically beneficial biological effects in vitro and in vivo. When used alone, ML120B elicited modest therapeutic gains. However, there was significant synergy with the microtubule inhibitor, vincristine. Our data indicate that approaches to NF-κB pathway inhibition are best used in combination with cytotoxic chemotherapy rather than single agents. The major future challenge is to develop a more effective IKK-2 inhibitor with lower cellular IC50 in order to make them more attractive clinically.

Materials and methods

Cell Culture and Reagents
The cell lines used in the study have been previously described; Follicular Lymphoma (WSU-FSCCL) [36] and Diffuse Large Cell Lymphoma (WSU-DLCL2) [37]; The WSU-FSCCL cell line has been karyotyped at least 4 times since our initial publication in 1993. The recent analysis in September of 2009 revealed the same chromosomal abnormalities as previously reported; 47,XY, +der(1)i(1)(q10)del(1)(q32),t(1;13)(p31;q12),del(6)(q21q27),t(8;11)(q24;q22),t(14;18)(q32;q21). The WSU-DLCL2 has been similarly karyotyped several times since its establishment in 1990. The cell line acquired an additional abnormality, add(8q24), that was detected for the first time in 1997. Since then the karyotype profile has remained stable with no further changes. The most recent karyotype in September of 2009 revealed: 48,XY,t(1;2)(p36;q37),der(3)t(3;7)(q13;p15),t(4;14)(q27;q32),+7,i(7)(p10),der(7)t(3;7)(q21;p11.2),+8,add(8)(q24),
t(14;18)(q32;q21), del(15)(q26.1), del(16)(q22)[10]. Furthermore, fluorescent in situ hybridization (FISH) using LSI MYC dual color break-apart DNA probe (Vysis Inc.) revealed a deletion of the telomeric 3′ region of CMYC gene most likely due to unbalanced translocation affecting the CMYC gene region. Cells were maintained in RPMI-1640 medium containing 10% heat-inactivated fetal bovine serum (FBS), 1% L-glutamine, 100 U/ml penicillin G and 100 μg/ml streptomycin and incubated at 37°C in a humidified incubator with 95%/5% CO₂. Primary antibody specific for Actin was obtained from Santa Cruz Biotechnology, (Santa Cruz, CA). Primary antibodies specific for Caspase-9, PARP, p-IκBα and IκBα were obtained from Cell Signaling, (Danvers, MA). G3PDH was obtained from Trevigen, Inc (Gaithersburg, MD). Protein concentrations were determined using the Micro BCA protein assay (Pierce Chemical Company, Rockford, IL). Cyclophosphamide monohydrate was obtained from Mead Johnson (Evansville, IN). Doxorubicin hydrochloride was obtained from Bedford Inc (SA, Australia). Vin- cristine was obtained from Pharma Inc. (Bloomington, MN). ML120B was synthesized by Millennium Pharmaceuticals, Inc (Cambridge, MA) and dissolved in DMSO. Concentration of DMSO in the final culture was 0.44%.

**Western Blot Analysis**

Proteins obtained from cell extracts were collected 24, 48, or 72 h after single or combination treatment with the IKK-2 inhibitor (ML120B) and vincristine in lysis buffer containing protease inhibitors. Cytosolic protein extracts were prepared from control and treated cells using Nuclear/Cytosolic Fractionation Kit according to manufacturer’s protocol (BioVision, Mountain View, CA). All proteins were resolved using 12% SDS-PAGE and transferred to Hybond C-extra membranes.

---

**Figure 8** In vivo activity of ML120B alone, and with CHOP in WSU-DLCL2-SCID xenograft mouse model, tumor weights represent Mean and standard error of mean (SEM). A. Activity of ML120B as single agent: WSU-DLCL2 tumors were xenografted s.c. into 10 ICR SCID mice/group on day 0 and dosing was initiated on day 7. ML120B was administered p.o. 120 mg/kg one dose on day 7 (x 1), 60 mg/kg twice (BID) on day 7 (x 2), and 60 mg/kg BID for 28 days starting on day 7 (x 28). Each point represents mean tumor weight of animal in each group ± SEM. B. ML120B plus CHOP treatment: Xenografts were developed as in A and treatment started on day 7. CHOP was administered at maximum tolerated doses (MTD) as previously defined (see Material and Methods), ML120B was administered p.o. 60 mg/kg BID for 28 days (as in A), ML120B in combination with CHOP at MTD.

| Treatment | P Value |
|-----------|---------|
| 2 vs 1    | 0.45    |
| 3 vs 1    | 0.35    |
| 4 vs 1    | 0.04    |
| 4 vs 2    | 0.03    |
| 4 vs 3    | 0.03    |
Flow Cytometric Analysis of Cell Cycle and Apoptosis

Cell cycle analysis and sub G0/G1 DNA content were determined by flow cytometry using propidium iodide (PI) staining. Cells were grown in the presence or absence of ML120B or vincristine then centrifuged and washed. The cells were then fixed with 75% cold ethanol overnight and stained with 50 μg of PI and analyzed.

To determine DNA fragmentation (as indication of apoptosis) induced by treatment agents, we utilized standard terminal deoxynucleotidyl transferase of dUTP nick end labeling (TUNEL) assay and propidium iodide (PI) staining. The kit used in this method (ApoDirect In Situ DNA Fragmentation Assay Kit, BioVision, Mountain View, CA; Catalog #K402-50) utilizes terminal deoxynucleotidyl transferase of dUTP nick end labeling (TUNEL) assay and propidium iodide (PI) staining. The kit used in this method (ApoDirect In Situ DNA Fragmentation Assay Kit, BioVision, Mountain View, CA; Catalog #K402-50) utilizes terminal deoxynucleotidyl transferase of dUTP nick end labeling (TUNEL) assay and propidium iodide (PI) staining. The kit used in this method (ApoDirect In Situ DNA Fragmentation Assay Kit, BioVision, Mountain View, CA; Catalog #K402-50) utilizes terminal deoxynucleotidyl transferase of dUTP nick end labeling (TUNEL) assay and propidium iodide (PI) staining. The kit used in this method (ApoDirect In Situ DNA Fragmentation Assay Kit, BioVision, Mountain View, CA; Catalog #K402-50) utilizes terminal deoxynucleotidyl transferase of dUTP nick end labeling (TUNEL) assay and propidium iodide (PI) staining.

To initiate the WSU-DLCL2-SCID xenografts, (5-10) × 10^6 WSU-DLCL2 cells in serum-free RPMI 1640 medium were injected subcutaneously (SC) in the flank areas of each animal. Palpable tumors were detected by clinical examination in about 2 weeks. When tumor weight reached 1000-1500 mg, animals were euthanized; tumors dissected out, placed in RPMI 1640 medium in sterile environment and minced into small fragments (20-30 mg each). To propagate the xenografts, tumor fragments were implanted SC, using a trocar, into flanks of 3-4 week old female ICR mice with severe combined immune deficiency (SCID) were purchased from Tacomb Farms (Germantown, NY). Animals were housed in special protective environment and left to adapt for few days before beginning the experiments. To initiate the WSU-DLCL2-SCID xenografts, (5-10) × 10^6 WSU-DLCL2 cells in serum-free RPMI 1640 medium were injected subcutaneously (SC) in the flank areas of each animal. Palpable tumors were detected by clinical examination in about 2 weeks. When tumor weight reached 1000-1500 mg, animals were euthanized; tumors dissected out, placed in RPMI 1640 medium in sterile environment and minced into small fragments (20-30 mg each). To propagate the xenografts, tumor fragments were implanted SC, using a trocar, into flanks of 3-4 week old female ICR-SCID mice. Forty animals were implanted with WSU-DLCL2 tumors for the single agent (ML120B alone) experiment and forty for the combination study (CHOP plus ML120B). The WSU-FSCCL-SCID is a systemic model which is established by injecting 10^7 WSU-FSCCL cells in serum-free medium intravenously via tail vein of ICR-SCID mice. The growth pattern and assessment of response of this model to ML120B were the same as previously published from our laboratory [25].

Efficacy Trial Design

WSU-DLCL2 tumor-bearing animals were randomly assigned to control or one of 3 treatment
dose/schedules of ML120B; 10 animals in each group. Therapy was started one week after tumor implantation. Group 1 received one dose of ML120B at 120 mg/kg. Group 2 received 60 mg/kg twice (every 12 hours). Group 3 received 60 mg/kg twice a day for 28 days. All treatments were given through oral gavage. ML120B compound was dissolved in 5% (hydroxypropyl) methylcellulose. Control group animals received vehicle alone. CHOP MTD in SCID mice was previously determined in our laboratory [21] for one injection (i.e. 40 mg/kg, i.v. cyclophosphamide; 3.3 mg/kg, i.v. doxorubicin; 0.5 mg/kg, i.v. vincristine; and 0.2 mg/kg orally prednisone every day for 5 days). Animals were monitored 3 times per week for signs of toxicity, weight changes and tumor measurements. They were euthanized to avoid discomfort if the tumor burden reached ~2000 mg (approximately 10% of the body weight). All animal experiments were done according to protocols approved by the Animal Investigation Committee (AIC) of Wayne State University.

Statistical Analysis

Statistical significance of drug-treated versus control measurements was determined by the student t-test. The interaction between ML120B and vincristine was analyzed using Calcusyn V2 software program to determine if the combinations were synergistic. Calcusyn is based on the Chou-Talalay method [40], which calculates a combinational index (CI) to indicate synergistic effects where CI < 0.9, is considered synergistic. Survival functions were estimated using the Kaplan-Meier method and compared by the log-rank test. P-values <0.05 were considered statistically significant.

All statistical analyses were evaluated using GraphPad Prism 4 (San Diego, CA).

Acknowledgements

Flow cytometry core: Eric Van Buren and Claire Lee. We thank Dr Ben Chen, Kristina Cole, Anton Scott Goustin, and Anshu Giri for their valuable input. Flow cytometry core: Eric Van Buren and Claire Lee. We thank Dr Ben Chen, Acknowledgements

Prism 4 (San Diego, CA).

References

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009, 59:225-249.
2. A clinical evaluation of the International Lymphoma Study Group classification of non Hodgkin’s lymphoma. The Non-Hodgkin’s Lymphoma Classification Project. Blood 1997, 89:3909-3918.
3. Young GA, Ishii J. Clinical perspectives in lymphoma. Intern Med J 2007, 37:478-484.
4. Toftdahl S, Betranelli M, Shankardass N, Shavridze N, Sekurina N. Treatment of aggressive non-Hodgkin’s lymphomas. Georgian Med News 2007, 145:30-33.
5. Schultz H, Bohlus J, Skoetz N, Trille S, Kober T, Reiser M, Dreyling M, Herold M, Schwarzer G, Halff M, Engert A. Chemotherapy plus Rituximab versus chemotherapy alone for B-cell non-Hodgkin’s lymphoma. Cochrane Database Syst Rev 2007, 4:CD003805.
6. Buske C, Weigert O, Dreyling M, Unterhalt M, Hiddemann W. Current status and perspective of antibody therapy in follicular lymphoma. Haematologica 2006, 91:104-112.
7. Bernal-Mizrachi L, Lovly CM, Ratner L. The role of NF-(kappa)B-1 and NF-(kappa)B-2-mediated resistance to apoptosis in lymphoma. Proc Natl Acad Sci USA 2006, 103:9220-9225.
8. Hayden MS, Ghosh S. Shared principles in NF-kB signaling. Cell 2008, 132:344-362.
9. Baezeres DS, Baldwin AS. Nuclear factor-kappaB and inhibitor of kappaB kinase pathways in oncogenic initiation and progression. Oncogene 2006, 25:6817-6830.
10. Mayo MW, Baldwin AS. The transcription factor NF-kappaB: control of oncogenesis and cancer therapy resistance. Biochim Biophys Acta 2000, 1474:155-62.
11. Escarego RO, Fuentes-Alexandro S, Garcia-Carrasco M, Gatica A, Zamora A. The transcription factor nuclear factor-kappaB B and cancer. Clin Oncol (R Coll Radatr) 2007, 19:154-161.
12. Heckman CA, Meheuw JW, Boxer LM. NF-kappaB-2 activates Bcl-2 expression in t(14;18) lymphoma cells. Oncogene 2002, 21:3898-3908.
13. Heckman CA, Cao T, Somsook L, Duan H, Meheuw JW, Zhang CY, Boxer LM. Critical elements of the immunoglobulin heavy chain gene enhancers for deregulated expression of bcl-2. Cancer Res 2003, 63:6666-6673.
14. Duan H, Heckman CA, Boxer LM. The immunoglobulin heavy-chain gene 3’ enhancers deregulate bcl-2 promoter usage in t(14;18) lymphoma cells. Oncogene 2007, 26:3635-3641.
15. Baldwin AS. The NF-kappaB B and I kappaB proteins: new discoveries and insights. Annu Rev Immunol 1996, 14:649-683.
16. Karrin M. Nuclear factor-kappaB in cancer development and progression. Nature 2006, 441:431-436.
17. Baldwin AS. Control of oncogenesis and cancer therapy resistance by the transcription factor NF-kappaB. J Clin Invest 2001, 107:241-246.
18. Jost PJ, Ruland J. Aberrant NF-kappaB signaling in lymphoma: mechanisms, consequences, and therapeutic implications. Blood 2007, 109:2700-2707.
19. Braddock M. 11th annual Inflammatory and Immune Diseases Drug Discovery and Development Summit 12-13 March 2007, San Francisco, USA. Expert Op Invest Drugs 2007, 16:909-917.
20. Hideshima T, Neri P, Tassone P, Yashu H, Ishitsuka K, Raje N, Chauhan D, Poddar K, Mitsiades C, Dang L, Munshi N, Richardson P, Schenkein D, Anderson KC. MLN120B, a novel IKappaB kinase beta inhibitor, blocks...
multiple myeloma cell growth in vitro and in vivo. Clin Cancer Res 2006, 12:5875-5884.

21. Mohammad RM, Kucuk O, Aboukameel A, Ibrahim D, Doerge DR, Sarkar F, Al-Katib AM. Genistein sensitizes diffuse large cell lymphoma to CHOP (cyclophosphamide, doxorubicin, vinblastine, prednisone) chemotherapy. Mol Cancer Ther 2009, 8:13-21.

22. Mujagic H, Chen SS, Geist R, Occhipinti SJ, Conger BM, Smith CA, Schuette WH, Shackney SE. Effects of vincristine on cell survival, cell cycle progression, and mitotic accumulation in asynchronously growing Sarcoma 180 cells. Cancer Res 1983, 43:3591-3597.

23. Shinwari Z, Manogaran PS, Afroz S, Al-Hussein KA, Aboussekhra A. Vincristine and lomustine induce apoptosis and p21(WAF1) up-regulation in medulloblastoma and normal human epithelial and fibroblast cells. J Neuro Oncol 2008, 87:123-132.

24. Wang L, MacDonald RC. Effects of microtubule-depolymerizing agents on the transfection of cultured vascular smooth muscle cells: enhanced expression with free drug and especially with drug–gene lipoplexes. Mol Ther 2004, 9:729-737.

25. Mohammad R, Abubakr Y, Dan M, Aboukameel A, Chow C, Mohamed A, Hamdy N, Al-Katib A. Bcl-2 Antisense oligonucleotides are effective against systemic but not central nervous system disease in Severe Combined Immuno Deficient mice bearing human t(14;18) follicular lymphoma. Clin Cancer Res 2002, 8:1277-1283.

26. Garcia MG, Alani L, Lopes EC, Blanco G, Hajoos SE, Alvarez E. Inhibition of NF-kappaB activity by BAY 11-7082 increases apoptosis in multidrug resistant leukemic T-cell lines. Leuk Res 2005, 29:1425-1434.

27. Greten FR, Karin M. The IKK/NF-kappaB activation pathway-a target for prevention and treatment of cancer. Cancer Lett 2004, 206:193-199.

28. Karin M, Yamamoto Y, Wang QM. The IKK NF-kappa B system: a treasure trove for drug development. Nat Rev Drug Discov 2004, 3:17-26.

29. Wen D, Nong Y, Morgan JG, Gangurde P, Bielecki A, Dasilva J, Keaveney M, Cheng H, Fraser C, Schoepf L, Hepperle M, Harriman G, Jaffee BD, Ocnain TD, XU Y. A selective small molecule IxB kinase B inhibitor blocks nuclear factor-kappaB-mediated inflammatory responses in human fibroblast-like synoviocytes, Chondrocytes, and Mast Cells. J Pharmacol Exp Ther 2006, 317:989-1000.

30. Nakajima H, Fujiwara H, Furuchi Y, Tanaka K, Shimbara N. A novel small-molecule inhibitor of NF-kappaB signaling. Biochem Biophys Res Commun 2008, 368:1007-1013.

31. Huang Y, Fang Y, Wu J, Dzadyk JM, Zhu H, Sui M, Fan W. Regulation of Vinca alkaloid-induced apoptosis by NF-kappaB/IxB pathway in human tumor cells. Mol Can Ther 2004, 3:271-277.

32. Chen X, Kandasamy K, Sivastava RK. Differential roles of RelA (p65) and c-Rel subunits of nuclear factor kappa B in tumor necrosis factor-related apoptosis-inducing ligand signaling. Cancer Res 2003, 63:1059-1066.

33. Wuerzburger-Davis SM, Chang PT, Berchtold CI, Miyamoto S. Enhanced G2-M arrest by nuclear factor-kappaB-dependent p21waf1/cip1 induction. Mol Cancer Res 2005, 3:345-353.

34. Bharti AC, Takada Y, Aggarwal BB. Curcumin (diferuloylmethane) down-regulates the constitutive activation of nuclear factor-kappa B and IkappaBalpha kinase in human multiple myeloma cells, leading to suppression of proliferation and induction of apoptosis. Blood 2003, 101:1053-1062.

35. Sanda T, Iida S, Ogura H, Asamitsu K, Murata T, Bacon KB, Ueda R. Enhanced G2-M arrest by nuclear factor-kappaB-dependent p21waf1/cip1 induction. Mol Cancer Res 2005, 3:345-353.

36. Mohammad RM, Mohamed AN, Smith MR, Jawadi NS, Al-Katib A. A unique EBV-negative low-grade lymphoma line (WSU-FSCCL) exhibiting both t(14;18) and t(8;11). Cancer Gene Cytogene 1993, 70:62-67.

37. Al-Katib AM, Smith MB, Kamanda WS, Perri G, Hamdan M, Mohamed AN, Chelladurai B, Mohammad RM. Bryostatin 1 down-regulates mdr1 and potentiates vincristine cytotoxicity in diffuse large cell lymphoma xenografts. Clin Cancer Res 1998, 4:1305-1314.

38. Darzyynkiewcz Z, Galkowski D, Zhao H. Analysis of apoptosis by cytometry using TUNEL assay. Methods 2008, 44:250-254.

39. Mohammad RM, Wang S, Aboukameel A, Chen B, Wu X, Chen J, Al-Katib A. Preclinical studies of a nonpeptidic small-molecule inhibitor of Bcl-2 and Bcl-xL(–)gossypol against diffuse large cell lymphoma. Mol Cancer Ther 2005, 4:13-21.

40. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984, 22:27-55.